Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Gregorc, Vanesa, Dr, Novello, Silvia, MD, Lazzari, Chiara, MD, Barni, Sandro, MD, Aieta, Michele, MD, Mencoboni, Manlio, MD, Grossi, Francesco, MD, Pas, Tommaso De, MD, de Marinis, Filippo, MD, Bearz, Alessandra, MD, Floriani, Irene, PhD, Torri, Valter, MD, Bulotta, Alessandra, MD, Cattaneo, Angela, Grigorieva, Julia, PhD, Tsypin, Maxim, PhD, Roder, Joanna, PhD, Doglioni, Claudio, Prof, Levra, Matteo Giaj, MD, Petrelli, Fausto, MD, Foti, Silvia, MD, Viganò, Mariagrazia, MD, Bachi, Angela, PhD, Roder, Heinrich, PhD
Published in The lancet oncology (01.06.2014)
Published in The lancet oncology (01.06.2014)
Get full text
Journal Article